Dergiler / Neurological sciences and neurophysiology (Online) / 2020 / Cilt: 37 - Sayı: 3

Serum Immunoglobulin G of Neuro‑Behçet’s Disease Patients Reduce Cerebral Expression Levels of Survival Pathway Factors

Sayfa
118–123
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Further identification of the binding sites of serum IgG ıs required.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Anti‑neuronal antibodies are found in sera of neuro‑Behçet’s disease (NBD) patients.
📊
Temel Bulgular & Veri:Locomotor activity was assessed by open field test on days 0, 10, and 25.
💡
Sonuç & Katkı:Further identification of the binding sites of serum IgG ıs required.
🔬Tür:Laboratuvar & Saha Deneyi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Anti‑neuronal antibodies are found in sera of neuro‑Behçet’s disease (NBD) patients. In this study, our aim was to analyze the potential mechanisms by which NBD immunoglobulin (Ig) Gs affect neuronal dysfunction. Materials and Methods: Purified IgGs obtained from pooled sera of six each NBD patients and healthy controls (HCs) were administered to Sprague Dawley rats through intraventricular injection. Control rats received phosphate‑buffered saline (PBS) only. Locomotor activity was assessed by open field test on days 0, 10, and 25. Cerebral expression levels of intracellular pathway factors associated with cell survival and viability were measured by real‑time polymerase chain reaction. Results: Rats treated with NBD IgG exhibited reduced motor activity. On day 25, the mean number of crossings was 44 ± 7, 90 ± 12, and 93 ± 5 and the mean number of rearings was 18 ± 7, 34 ± 5, and 35 ± 6 for NBD IgG, HC IgG, and PBS groups, respectively (P < 0.001). Relative expression levels of Akt‑1 (0.4 ± 0.2, 1.0 ± 0.3, and 0.9 ± 0.6; P = 0.004), DJ‑1 (0.6 ± 0.2, 1.0 ± 0.6, and 0.9 ± 0.5; P = 0.047), mouse double mininute‑2 (0.5 ± 0.3, 0.9 ± 0.2, and 1.0 ± 0.2; P = 0.002), and mechanistic target of rapamycin (0.4 ± 0.2, 0.8 ± 0.4, and 0.9 ± 0.6; P = 0.006) were significantly lower in NBD‑IgG group than HC IgG and PBS groups. By contrast, the expression levels of factors associated with apoptosis (caspase 3, mitochondrial carrier homolog 1, and B‑cell lymphoma‑2) were comparable among different treatment arms. Conclusion: Our results suggest that at least a fraction of NBD IgG interacts with neuronal surface antigens and subsequently decreases neuronal viability through Akt pathway inhibition. By contrast, NBD IgG does not appear to activate neuronal apoptosis. Further identification of the binding sites of serum IgG ıs required.

🔖

Bu Makaleye Atıf Yap

ERDAĞ, E., ÖZKARTAL, C. Ş., ARICIOĞLU, F., KÜÇÜKALİ, C. İ., TÜZÜN, E. (2020). Serum Immunoglobulin G of Neuro‑Behçet’s Disease Patients Reduce Cerebral Expression Levels of Survival Pathway Factors. Neurological sciences and neurophysiology (Online), Cilt: 37 - Sayı: 3, 118–123. https://ajindex.com/articles/290539

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (17)

  1. Seyahi E, Phenotypes in Behçet’s syndrome. Intern Emerg Med 2019;14:677‑89
  2. Uygunoğlu U, Siva A. Nervous system involvement in Behçet’s syndrome. Curr Opin Rheumatol 2019;31:32‑9
  3. Kürtüncü M, Tüzün E, Akman‑Demir G. Behçet’s disease and nervous system involvement. Treat Options Neurol 2016;18:19
  4. Kidd DP. Neurological complications of Behçet’s syndrome. J Neurol 2017;264: 2178‑83
  5. Erdağ E, Şahin C, Küçükali Cİ, Bireller S, Küçükerden M, Kürtüncü M, et al. Effects of in vivo and in vitro administration of Neuro‑Behcet’s disease IgG. Neurol Sci 2017;38:833‑43
  6. Lule S, Colpak AI, Balci‑Peynircioglu B, Gursoy‑Ozdemir Y, Peker S, Kalyoncu U, et al. Behçet disease serum is immunoreactive to neurofilament medium which share common epitopes to bacterial HSP‑65, a putative trigger. J Autoimmun 2017;84:87‑96
  7. Celet B, Akman‑Demir G, Serdaroğlu P, Yentür SP, Taşci B, van Noort JM, et al. Anti‑alpha B‑crystallin immunoreactivity in inflammatory nervous system diseases. J Neurol 2000;247:935‑9
  8. Gheita TA, Samir H, Hussein H. Anti‑annexin V antibodies in neuro‑Behçet patients: Clinical significance and relation to disease activity. Int J Rheum Dis 2012;15:e124‑6
  9. Vural B, Uğurel E, Tüzün E, Kürtüncü M, Zuliani L, Cavuş F, et al. Anti‑neuronal and stress‑induced‑phosphoprotein 1 antibodies in neuro‑Behçet’s disease. J Neuroimmunol 2011;239:91‑7
  10. Giriş M, Bireller S, Küçükali Cİ, Hanağasi H, Değirmencioğlu S, Tüzün E. Impact of neuro‑Behçet disease immunoglobulin G on neuronal apoptosis. Noro Psikiyatr Ars 2017;54:67‑71
  11. International Study Group for Behcet’s Disease. Criteria for diagnosis of Behcet’s disease. Lancet 1990;335:1078‑80
  12. Marquard FE, Jücker M. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. Biochem Pharmacol. 2020;172:113729s
  13. Guerrero‑Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: Role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev 2016;35:515‑24
  14. Wang H, Gao W. DJ‑1 Expression in cervical carcinoma and its effects on cell viability and apoptosis. Med Sci Monit 2016;22:2943‑9
  15. Chen SR, Cai WP, Dai XJ, Guo AS, Chen HP, Lin GS, et al. Research on miR‑126 in glioma targeted regulation of PTEN/PI3K/Akt and MDM2‑p53 pathways. Eur Rev Med Pharmacol Sci 2019;23:3461‑70
  16. Munson MJ, Ganley IG. MTOR, PIK3C3, and autophagy: Signaling the beginning from the end. Autophagy 2015;11:2375‑6
  17. Zheng M, Yu H, Zhang L, Li H, Liu Y, Kijlstra A, et al. Associat